Overview

* InspireMD ( NSPR ) Q2 revenue rises 2.3%, beating analyst expectations, per LSEG data

* Net income for Q2 missed analyst expectations, per LSEG data

* Co received FDA approval and launched CGuard Prime in U.S. market

Outlook

* Company plans to launch CGuard Prime in Europe in Q3

* InspireMD ( NSPR ) focuses on scaling operations post-U.S. launch

* Company aims to establish CGuard as standard for carotid disease

Result Drivers

* FDA APPROVAL - Received FDA approval for CGuard Prime carotid stent system, driving U.S. market launch

* EXCHANGE RATES - Revenue positively impacted by exchange rates, offsetting decreased revenue from Russia

* OPERATING EXPENSES - Increased due to U.S. sales force expansion and CGuard Prime launch preparation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.78 $1.52

Revenue mln mln (2

Analysts

)

Q2 Net Miss -$13.15 -$12.90

Income mln mln (2

Analysts

)

Q2 Beat -$13.02 -$13.10

Income mln mln (2

From Analysts

Operatio )

ns

Q2 Basic -$0.26

EPS

Q2 Gross $313,000

Profit

Q2 $13.33

Operatin mln

g

Expenses

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)